Ascendis Pharma A/S
NASDAQ:ASND
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
112.93
159.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Ascendis Pharma A/S
Ascendis Pharma A/S
Current Portion of Long-Term Debt
Ascendis Pharma A/S
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Current Portion of Long-Term Debt
€27.7m
|
CAGR 3-Years
60%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Current Portion of Long-Term Debt
kr94m
|
CAGR 3-Years
17%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Current Portion of Long-Term Debt
kr15.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Current Portion of Long-Term Debt
kr41.9m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
21%
|
CAGR 10-Years
17%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Current Portion of Long-Term Debt
kr2.2m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
60%
|
|
|
Saniona AB
STO:SANION
|
Current Portion of Long-Term Debt
kr4.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ascendis Pharma A/S
Glance View
Ascendis Pharma A/S has established itself as a dynamic force within the biotechnology sphere, driven by a patented technology platform designed to address unmet medical needs. Founded in 2006 and headquartered in Denmark, the company has honed its focus on developing therapies to improve patients' lives by addressing significant health conditions, primarily in the fields of endocrinology and oncology. At the heart of its strategy is the TransCon technology, which revolves around prodrug methodologies that release active drug molecules at controlled rates, enhancing efficacy and reducing side effects. This platform allows Ascendis to develop extended-release versions of existing drugs, ensuring a more sustained therapeutic effect. Financially, Ascendis generates revenue by forging strategic partnerships and licensing agreements, enabling it to share in the commercialization success of its innovative pipeline products. By collaborating with larger pharmaceutical firms, Ascendis scales its impact, leveraging shared resources and expertise to bring its specialized treatments to market. Moreover, as its pipeline matures, it seeks to capitalize on successful clinical trials by moving products into commercial phases, which can result in additional income streams from direct product sales. The journey of Ascendis Pharma is emblematic of its commitment to innovation, sustainability, and delivering tangible healthcare advances through its robust technology-driven approach.
See Also
What is Ascendis Pharma A/S's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
27.7m
EUR
Based on the financial report for Sep 30, 2024, Ascendis Pharma A/S's Current Portion of Long-Term Debt amounts to 27.7m EUR.
What is Ascendis Pharma A/S's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
39%
Over the last year, the Current Portion of Long-Term Debt growth was 5%. The average annual Current Portion of Long-Term Debt growth rates for Ascendis Pharma A/S have been 60% over the past three years , 39% over the past five years .
You don't have any saved screeners yet
